Ticker

CHICAGO, IL / ACCESS Newswire / April 30, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it is projecting Cur18™ to generate over $2.5 million in incremental annual revenue in the United States within the next 12 to 18 months, based on its current commercialization strategy and internal assumptions.…

Science-first nutraceutical platform: Every "18" product must clear three criteria before reaching market - a patented ingredient, peer-reviewed clinical evidence, and the exact dose studied in clinical trials; a bar the vast majority of the supplement industry cannot meet Three products introduced, $7.8 billion addressable market: Noor18™, Liv18™, and Cur18™ - targeting healthy aging & beauty, liver & metabolic…

Phase 1 complete: product development, packaging, and initial commercial setup finalized ahead of schedule Production commencing April 2026: GMP-certified, FDA-registered, UL-audited U.S. manufacturing - mitigating tariff risk $5M+ projected annual revenue: Liv18™ expected to generate over $5 million annually at approximately 75% gross margins Direct-to-consumer model: scalable DTC strategy with targeted advertising…

Clinically studied curcumin formulation demonstrating significantly enhanced absorption versus standard 95% curcuminoid extracts. Derived predominantly from turmeric (~98.5%), maintaining a composition closer to the natural profile of the plant.

CHICAGO, IL / ACCESS Newswire / April 16, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the continued integration of artificial intelligence (AI) across its operations, reflecting ongoing investments aimed at enhancing efficiency, reducing costs, improving customer experience, and driving sales growth. AI is…